INTERWEST VENTURE MANAGEMENT CO - Q2 2021 holdings

$317 Million is the total value of INTERWEST VENTURE MANAGEMENT CO's 10 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 16.7% .

 Value Shares↓ Weighting
PMVP SellPMV PHARMACEUTICALS INC$169,772,000
-5.6%
4,969,911
-9.1%
53.57%
+13.2%
AI SellC3.AIcl a$54,199,000
-40.7%
866,774
-37.5%
17.10%
-28.9%
REAL  THE REALREAL$46,517,000
-12.7%
2,354,0800.0%14.68%
+4.7%
GKOS  GLAUKOS CORP$29,382,000
+1.1%
346,3640.0%9.27%
+21.2%
EIGR  EIGER BIOPHARMACEUTICALS INC$6,517,000
-3.7%
764,9180.0%2.06%
+15.4%
AGTC  APPLIED GENETIC TECHNOL CORP$5,492,000
-22.9%
1,404,5150.0%1.73%
-7.5%
CDTX  CIDARA THERAPEUTICS INC$2,741,000
-24.1%
1,356,8130.0%0.86%
-8.9%
VERO  VENUS CONCEPT INC$2,048,000
+32.3%
658,6570.0%0.65%
+58.7%
XENE  XENON PHARMACEUTICALS INC$148,0000.0%8,2930.0%0.05%
+20.5%
DARE  DARE BIOSCIENCE INC$95,000
+11.8%
50,3680.0%0.03%
+36.4%
ExitOBALON THERAPEUTICS INC$0-380,224
-100.0%
-0.28%
STIM ExitNEURONETICS INC$0-497,158
-100.0%
-1.62%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-07-26
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
GLAUKOS CORP28Q3 202333.0%
EIGER BIOPHARMACEUTICALS INC24Q3 202217.7%
APPLIED GENETIC TECHNOL CORP24Q3 20226.7%
XENON PHARMACEUTICALS INC20Q3 20210.6%
CIDARA THERAPEUTICS INC19Q2 20214.5%
THE REALREAL18Q3 202362.6%
KALVISTA PHARMACEUTICALS INC17Q4 202010.8%
DARE BIOSCIENCE INC16Q3 20230.3%
MACROGENICS INC14Q1 202019.2%
PMV PHARMACEUTICALS INC13Q3 202367.5%

View INTERWEST VENTURE MANAGEMENT CO's complete holdings history.

Latest filings
TypeFiled
1442024-02-27
13F-HR2023-10-20
13F-HR2023-07-21
13F-HR2023-04-27
13F-HR2023-01-31
13F-HR2022-10-25
13F-HR2022-08-02
13F-HR2022-04-13
13F-HR2022-01-25
13F-HR2021-10-19

View INTERWEST VENTURE MANAGEMENT CO's complete filings history.

Compare quarters

Export INTERWEST VENTURE MANAGEMENT CO's holdings